Table 4.
Recent reports on fibrolamellar hepatocellular carcinoma from the European region (2009–2019)
| Report | Number of patients | Age (y) | Male/female | Initial clinical features | Stage | Number of lesions | Vascular invasion | Positive lymph nodes | Resection margin | Chemotherapy | Resection | Recurrence after surgery | OS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ince et al. [46] | 1 | 19 | 0/1 | Abdominal pain | NR | Mult | Microvasc | Yes | – | No | Unresectable | – | 26 m |
| Bill et al. [47] | 1 | 28 | 1/0 | Abdominal pain | NR | Mult | NR | NR | – | Palliative: sorafenib, doxorubicin, everolimus | Unresectable | – | 23 m |
| Mafeld et al. [44] | 1 | 52 | 0/1 | Abdominal discomfort | NR | 1 | Macrovasc | NR | R0 | Neoadjuvant: TACE, SIRT (Y-90) | Resected | – | NR |
| Ciurea et al. [48] | 1 | 23 | 0/1 | Abdominal pain, distended lower abdomen | NR | Mult | NR | NR | R0 | Adjuvant: cisplatin, 5-FU; sorafenib | Resected | Yes, at 26 m | 61 m |
| Estrella Diez et al. [49] | 1 | 16 | 1/0 | Weight loss, jaundice, abdominal pain | NR | 1 | NR | NR | – | Oxaliplatin, folinate calcium, 5-FU | Unresectable | – | NR |
| Bauer et al. [50] | 1 | 29 | 1/0 | Incidental finding | NR | 1 | NR | NR | NR | Adjuvant: sorafenib | Resected | Yes, within 24 m | NR |
| Bender et al. [51] | 1 | 19 | 0/1 | Elevated liver enzymes | NR | NR | NR | NR | NR | Sorafenib, bevacizumab, erlotinib, platinum, doxorubicin, gemcitabine | Resected | Yes, NR | NR |
| Vandewynckel et al. [52] | 1 | 26 | 1/0 | NR | NR | NR | NR | NR | – | Palliative: cisplatin, doxorubicin, sorafenib | Unresectable | – | NR |
| Sulaiman and Geberhiwot [53] | 1 | 14 | 0/1 | NR | NR | NR | NR | NR | NR | Adjuvant, sorafenib | Resected | Yes, within 3 y | 6 y |
| Chiarelli et al. [54] | 1 | 62 | 1/0 | NR | NR | 1 | NR | NR | NR | No | Resected | No, FU 36 m | NR |
| Okur et al. [55] | 1 | 12 | 0/1 | Weight loss, constipation, fatigue | NR | 3 | NR | Yes | R0 |
Neoadjuvant: cisplatin, doxorubicin Adjuvant: cyclophosphamide, thalidomide; 5-FU, IFN-α |
Resected | Yes, at 21 m | NR |
| Zen et al. [56] | 14 | Median 19 (range 11–38) | 6/8 | NR | NR | NR | NR | NR | NR | No | Resected | NR | NR |
| Minutolo et al. [57] | 1 | 29 | 1/0 | RUQ pain, nausea, vomiting | NR | 1 | NR | NR | Rx (ruptured) | Adjuvant: NR | Resected | Yes, at 6 m | 26 m |
| De Gaetano et al. [58] | 1 | 25 | 1/0 | Abdominal pain, obstructive jaundice | NR | 1 | NR | No | R0 | No | Resected | No, FU 36 m | NR |
| Berger et al. [59] | 1 | 22 | 0/1 | Weight loss, constipation, vomiting | NR | Mult | NR | Yes | – | Yes: bleomycin, etoposide, cisplatin | Unresectable | – | < 1 m |
| Wojcicki et al. [60] | 1 | 28 | 0/1 | NR | NR | 1 | NR | Yes | NR | No | Resected | Yes, at 23 m | 114 m |
| Gras et al. [61] | 1 | 25 | 0/1 | Mass of the right hypochondrium | NR | 1 | NR | NR | NR | Adjuvant: gemcitabine, oxaliplatin | Resected | Yes, at 6 m | 39 m |
| Malouf et al. [30] | 40 | Median 22 (range 9–65) | 9 (22%)/31 (78%) | Abdominal pain (55%), weight loss (25%), hepatomegaly |
AJCC: I (67%) II (0%) III (23%) IV (10%) |
1 (90%), mult (10%) | Microvasc (52%) | Yes (27%) | NR | Adjuvant (48%) | Resected | 23 pts within 7.8 y | 18 pts in 7.8 y |
| Benito et al. [45] | 1 | 26 | 0/1 | NR | NR | 1 | NR | NR | NR | Adjuvant: sunitinib | Resected | No, at 12 m | 12 m |
| Koudah et al. [62] | 1 | 24 | 1/0 | RUQ pain, weight loss | NR | 1 | NR | NR | NR | NR | Resected | NR | NR |
| Brunel et al. [63] | 1 | 22 | 0/1 | Abdominal pain, fever, palpable mass | NR | 1 | NR | No | NR | NR | Resected | No, at 25 m | 25 m |
| Mroz et al. [64] | 1 | 28 | 1/0 | Dyspnea, cough, hemoptysis, chest pain, fever, general weakness, left leg pain | NR | Mult. | NR | NR | NR | 5-FU, cisplatin, doxorubicin | Unresectable | – | NR |
| Terzis et al. [65] | 1 | 23 | 1/0 | Abdominal discomfort | NR | 1 | Macrovasc | NR | No | No | Unresectable | NR | NR |
5-FU 5-fluorouracil, NR not reported, m months, y years, pts patients, FU follow-up, mult multiple, RUQ right upper quadrant